Finmin nod for Rs 2,410 cr FDI proposalsIllustrative image – not actual.

The Ministry of Finance on recommendations of the FIPB has cleared 21 FDI proposals worth Rs 2,410 crore, including eight from the pharmaceutical sector.

The 21 FDI proposals include eight proposals worth Rs 1,842.55 crore relating FDI in brownfield pharmaceutical sector. However, the eight pharma proposals cleared by the board are subject to certain conditions. These pharma companies would be required to maintain for the next five years the quantitative level of NLEM (National List of Essential Medicines) drugs production annually at the time of induction of foreign investment.

Pfizer has obtained nod for "induction of foreign equity in an operating-cum-investing company to carry out the business in pharmaceutical sector" to the tune of Rs 800 crore. Mumbai based Arch Pharmalabs' proposal for inducting Rs 372 crore of foreign investment for manufacture and sale of active pharmaceutical ingredients has been approved.

Also Sterlite Networks, Dadar and Nagar Haveli, plan to bring in FDI worth Rs 500 crore for telecom business was cleared. The Wall Street Journal has been permitted for change in the foreign collaborator by way of overseas merger within group companies.

D B Corp has been given a go ahead to increase the foreign equity participation "to carry out the business of publication of newspapers including the business of developing, editing, publishing, printing, distributing and marketing newspapers and other publications and FM radio business.

Other proposals which have been given nod are those of Sutures India, Bangalore (Rs 200 crore), B Braun Singapore, Singapore (Rs 248.40 crore), Stellence Pharmscience, Bangalore (Rs 100 crore) and Zim Laboratories, Nagpur (Rs 50.44 crore).
 

← All latest storiesBack to top →